Advertisement

Pharmacologic Management of Agitation in Patients with Dementia

  • Cara L. McDermott
  • David A. GruenewaldEmail author
Palliative Care (D Wu, Section Editor)
  • 22 Downloads
Part of the following topical collections:
  1. Topical Collection on Palliative Care

Abstract

Purpose of Review

Agitation is common among older adults with dementia; its origin may be multi-factorial, and it is often difficult to treat. In this paper, we summarize current knowledge and offer considerations on pharmacologic management of behavioral and psychological symptoms of dementia (BPSD).

Recent Findings

We reviewed human studies published from 2013 to 2018 evaluating pharmacologic management of BPSD manifestations including depressive symptoms, mania, psychosis, and other BPSD, as well as severe agitation without determination of underlying cause. After non-pharmacological management is exhausted, the choice of pharmacological options depends on patient comorbidities, specific BPSD presentation, and patient tolerance of medications.

Summary

Depending on manifestations of BPSD, low- to moderate-quality evidence supports the use of anti-depressants, anti-psychotics, or anti-epileptics in conjunction with cholinesterase inhibitors. The current evidence base needs to be augmented with future research that focuses on real-world medication use alongside head-to-head evaluation of medication effectiveness rather than comparison to placebo.

Keywords

Aggression Agitation Alzheimer disease Behavior and psychological symptoms Dementia Medication 

Notes

Compliance with Ethical Standards

Conflict of Interest

Cara McDermott and David Gruenewald declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Disclosure

The contents of this article do not represent the views of the US Department of Veterans Affairs or the US Government.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology. 2013;80(19):1778–83.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Derby CA, Katz MJ, Lipton RB, Hall CB. Trends in dementia incidence in a birth cohort analysis of the Einstein aging study. JAMA Neurol. 2017;74(11):1345–51.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Rocca WA, Petersen RC, Knopman DS, Hebert LE, Evans DA, Hall KS, et al. Trends in the incidence and prevalence of Alzheimer’s disease, dementia, and cognitive impairment in the United States. Alzheimers Dement. 2011;7(1):80–93.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    van der Linde RM, Dening T, Stephan BC, Prina AM, Evans E, Brayne C. Longitudinal course of behavioural and psychological symptoms of dementia: systematic review. Br J Psychiatry. 2016;209(5):366–77.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Livingston G, Kelly L, Lewis-Holmes E, Baio G, Morris S, Patel N, et al. Non-pharmacological interventions for agitation in dementia: systematic review of randomised controlled trials. Br J Psychiatry. 2014;205(6):436–42.PubMedCrossRefGoogle Scholar
  6. 6.
    de Oliveira AM, Radanovic M, de Mello PC, Buchain PC, Vizzotto AD, Celestino DL, et al. Nonpharmacological interventions to reduce behavioral and psychological symptoms of dementia: a systematic review. Biomed Res Int. 2015;2015:218980.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Brasure M, Jutkowitz E, Fuchs E, Nelson VA, Kane RA, Shippee T, et al. Nonpharmacologic interventions for agitation and aggression in dementia. Rockville (MD): AHRQ Comparative Effectiveness Reviews; 2016.Google Scholar
  8. 8.
    Maust DT, Kales HC, McCammon RJ, Blow FC, Leggett A, Langa KM. Distress associated with dementia-related psychosis and agitation in relation to healthcare utilization and costs. Am J Geriatr Psychiatry. 2017;25(10):1074–82.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Suehs BT, Shah SN, Davis CD, Alvir J, Faison WE, Patel NC, et al. Household members of persons with Alzheimer’s disease: health conditions, healthcare resource use, and healthcare costs. J Am Geriatr Soc. 2014;62(3):435–41.PubMedCrossRefGoogle Scholar
  10. 10.
    Cummings JL, Geldmacher D, Farlow M, Sabbagh M, Christensen D, Betz P. High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer’s disease: drug profile and clinical guidelines. CNS Neurosci Ther. 2013;19(5):294–301.PubMedCrossRefGoogle Scholar
  11. 11.
    Cummings J, Lai TJ, Hemrungrojn S, Mohandas E, Yun Kim S, Nair G, et al. Role of donepezil in the management of neuropsychiatric symptoms in Alzheimer’s disease and dementia with Lewy bodies. CNS Neurosci Ther. 2016;22(3):159–66.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356(9247):2031–6.CrossRefGoogle Scholar
  13. 13.
    Bohnen NI, Kaufer DI, Ivanco LS, Lopresti B, Koeppe RA, Davis JG, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol. 2003;60(12):1745–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Wang J, Yu JT, Wang HF, Meng XF, Wang C, Tan CC, et al. Pharmacological treatment of neuropsychiatric symptoms in Alzheimer’s disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2015;86(1):101–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Cumbo E, Ligori LD. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer’s disease: a 12-month, randomized, open-label trial. J Alzheimers Dis. 2014;39(3):477–85.PubMedCrossRefGoogle Scholar
  16. 16.
    •• Carotenuto A, Rea R, Traini E, Fasanaro AM, Ricci G, Manzo V, et al. The effect of the association between donepezil and choline alphoscerate on behavioral disturbances in Alzheimer’s disease: interim results of the ASCOMALVA trial. J Alzheimers Dis. 2017;56(2):805–15 Interim results suggest addition of choline alphoscerate may result in reduced BPSD and decreased accompanying caregiver distress in patients with mild-moderate AD.PubMedCrossRefGoogle Scholar
  17. 17.
    Gareri P, Putignano D, Castagna A, Cotroneo AM, De Palo G, Fabbo A, et al. Retrospective study on the benefits of combined memantine and cholinesterase inhibitor treatMent in AGEd patients affected with Alzheimer’s disease: the MEMAGE study. J Alzheimers Dis. 2014;41(2):633–40.PubMedCrossRefGoogle Scholar
  18. 18.
    • Chen R, Chan PT, Chu H, Lin YC, Chang PC, Chen CY, et al. Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: a meta-analysis. PLoS One. 2017;12(8):e0183586 Analysis notes greater improvement in BPSD for patients with severe AD receiving combination therapy vs donepezil only.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Yoon SJ, Choi SH, Na HR, Park KW, Kim EJ, Han HJ, et al. Effects on agitation with rivastigmine patch monotherapy and combination therapy with memantine in mild to moderate Alzheimer’s disease: a multicenter 24-week prospective randomized open-label study (the Korean EXelon patch and combination with mEmantine comparative trial study). Geriatr Gerontol Int. 2017;17(3):494–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Manabe Y, Ino T, Yamanaka K, Kosaka K. Increased dosage of donepezil for the management of behavioural and psychological symptoms of dementia in dementia with Lewy bodies. Psychogeriatrics. 2016;16(3):202–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Seppala LJ, Wermelink A, de Vries M, Ploegmakers KJ, van de Glind EMM, Daams JG, et al. Fall-risk-increasing drugs: a systematic review and meta-analysis: II. Psychotropics. J Am Med Dir Assoc. 2018;19(4):371 e11–7.CrossRefGoogle Scholar
  22. 22.
    Seitz DP, Adunuri N, Gill SS, Gruneir A, Herrmann N, Rochon P. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011;2:CD008191.Google Scholar
  23. 23.
    •• Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311(7):682–91 RCT demonstrated efficacy of citalopram for management of BPSD.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Banerjee S, Hellier J, Romeo R, Dewey M, Knapp M, Ballard C, et al. Study of the use of antidepressants for depression in dementia: the HTA-SADD trial--a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. Health Technol Assess. 2013;17(7):1–166.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Farina N, Morrell L, Banerjee S. What is the therapeutic value of antidepressants in dementia? A narrative review. Int J Geriatr Psychiatry. 2017;32(1):32–49.PubMedCrossRefGoogle Scholar
  26. 26.
    Santa Cruz MR, Hidalgo PC, Lee MS, Thomas CW, Holroyd S. Buspirone for the treatment of dementia with behavioral disturbance. Int Psychogeriatr. 2017;29(5):859–62.PubMedCrossRefGoogle Scholar
  27. 27.
    Mizukami K, Hatanaka K, Tanaka Y, Sato S, Asada T. Therapeutic effects of the selective serotonin noradrenaline reuptake inhibitor milnacipran on depressive symptoms in patients with Alzheimer’s disease. Prog Neuro-Psychopharmacol Biol Psychiatry. 2009;33(2):349–52.CrossRefGoogle Scholar
  28. 28.
    Mokhber N, Abdollahian E, Soltanifar A, Samadi R, Saghebi A, Haghighi MB, et al. Comparison of sertraline, venlafaxine and desipramine effects on depression, cognition and the daily living activities in Alzheimer patients. Pharmacopsychiatry. 2014;47(4–5):131–40.PubMedGoogle Scholar
  29. 29.
    Lin CP, Chu CP, Liu HC. Bupropion improved apathy in behavioral variant frontotemporal dementia: a case report. Neurocase. 2016;22(5):466–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Martinon-Torres G, Fioravanti M, Grimley EJ. Trazodone for agitation in dementia. Cochrane Database Syst Rev. 2004;4:CD004990.Google Scholar
  31. 31.
    Camargos EF, Louzada LL, Quintas JL, Naves JO, Louzada FM, Nobrega OT. Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study. Am J Geriatr Psychiatry. 2014;22(12):1565–74.PubMedCrossRefGoogle Scholar
  32. 32.
    Tampi RR, Tampi DJ. Efficacy and tolerability of benzodiazepines for the treatment of behavioral and psychological symptoms of dementia: a systematic review of randomized controlled trials. Am J Alzheimers Dis Other Demen. 2014;29(7):565–74.PubMedCrossRefGoogle Scholar
  33. 33.
    Defrancesco M, Marksteiner J, Fleischhacker WW, Blasko I. Use of benzodiazepines in Alzheimer’s disease: a systematic review of literature. Int J Neuropsychopharmacol. 2015;18(10):pyv055.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Tampi RR, Tampi DJ, Balachandran S, Srinivasan S. Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses. Ther Adv Chronic Dis. 2016;7(5):229–45.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Kane JM, Correll CU, Nierenberg AA, Caroff SN, Sajatovic M, Tardive Dyskinesia Assessment Working G. Revisiting the Abnormal Involuntary Movement Scale: Proceedings From the Tardive Dyskinesia Assessment Workshop. J Clin Psychiatry. 2018;79(3).Google Scholar
  36. 36.
    Van Leeuwen E, Petrovic M, van Driel ML, De Sutter AI, Vander Stichele R, Declercq T, et al. Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2018;3:CD007726.PubMedGoogle Scholar
  37. 37.
    • Tjia J, Reidenberg MM, Hunnicutt JN, Paice K, Donovan JL, Kanaan A, et al. Approaches to gradual dose reduction of chronic off-label antipsychotics used for behavioral and psychological symptoms of dementia. Consult Pharm. 2015;30(10):599–611 Synthesizes data supporting proposed de-prescribing algorithm for patients receiving anti-psychotics.PubMedCrossRefGoogle Scholar
  38. 38.
    Mathys M, Fang S, John J, Carter J. Antipsychotic discontinuation after the initiation of selective serotonin reuptake inhibitors therapy for the treatment of behavioral and psychological symptoms associated with dementia. Ment Health Clin. 2018;8(3):122–6.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    •• Brodaty H, Aerts L, Harrison F, Jessop T, Cations M, Chenoweth L, et al. Antipsychotic deprescription for older adults in long-term care: the HALT study. J Am Med Dir Assoc. 2018;19(7):592–600 e7 Demonstrated that anti-psychotics may be safely withdrawn without increase in BPSD or adverse outcomes.PubMedCrossRefGoogle Scholar
  40. 40.
    Tariot PN, Schneider LS, Cummings J, Thomas RG, Raman R, Jakimovich LJ, et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry. 2011;68(8):853–61.PubMedCrossRefGoogle Scholar
  41. 41.
    Lonergan E, Luxenberg J. Valproate preparations for agitation in dementia. Cochrane Database Syst Rev. 2009;3:CD003945.Google Scholar
  42. 42.
    Gallagher D, Herrmann N. Antiepileptic drugs for the treatment of agitation and aggression in dementia: do they have a place in therapy? Drugs. 2014;74(15):1747–55.PubMedCrossRefGoogle Scholar
  43. 43.
    Suzuki H, Gen K. Clinical efficacy of lamotrigine and changes in the dosages of concomitantly used psychotropic drugs in Alzheimer’s disease with behavioural and psychological symptoms of dementia: a preliminary open-label trial. Psychogeriatrics. 2015;15(1):32–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Cooney C, Murphy S, Tessema H, Freyne A. Use of low-dose gabapentin for aggressive behavior in vascular and mixed vascular/Alzheimer dementia. J Neuropsychiatry Clin Neurosci. 2013;25(2):120–5.PubMedCrossRefGoogle Scholar
  45. 45.
    •• Cummings JL, Lyketsos CG, Peskind ER, Porsteinsson AP, Mintzer JE, Scharre DW, et al. Effect of dextromethorphan-quinidine on agitation in patients with alzheimer disease dementia: a randomized clinical trial. JAMA. 2015;314(12):1242–54 In short-term 10 week trial, authors found reduced agitation among AD patients taking dextromethorphan-quinidine.PubMedCrossRefGoogle Scholar
  46. 46.
    Tampi RR, Hassell C, Joshi P, Tampi DJ. Analgesics in the management of behavioral and psychological symptoms of dementia: a perspective review. Drugs Context. 2017;6:212508.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Habiger TF, Flo E, Achterberg WP, Husebo BS. The interactive relationship between pain, psychosis, and agitation in people with dementia: results from a cluster-randomised clinical trial. Behav Neurol. 2016;2016:7036415.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Devanand DP, Strickler JG, Huey ED, Crocco E, Forester BP, Husain MM, et al. Lithium treatment for agitation in Alzheimer’s disease (lit-AD): clinical rationale and study design. Contemp Clin Trials. 2018;71:33–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Carr CN, Straley CM, Baugh TB. Allopurinol for the treatment of refractory aggression: a case series. Pharmacotherapy. 2017;37(6):748–54.PubMedCrossRefGoogle Scholar
  50. 50.
    Wade AG, Farmer M, Harari G, Fund N, Laudon M, Nir T, et al. Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer’s disease: a 6-month, randomized, placebo-controlled, multicenter trial. Clin Interv Aging. 2014;9:947–61.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Schroeck JL, Ford J, Conway EL, Kurtzhalts KE, Gee ME, Vollmer KA, et al. Review of safety and efficacy of sleep medicines in older adults. Clin Ther. 2016;38(11):2340–72.PubMedCrossRefGoogle Scholar
  52. 52.
    McCleery J, Cohen DA, Sharpley AL. Pharmacotherapies for sleep disturbances in dementia. Cochrane Database Syst Rev. 2016;11:CD009178.PubMedGoogle Scholar
  53. 53.
    Butchart J, Brook L, Hopkins V, Teeling J, Puntener U, Culliford D, et al. Etanercept in Alzheimer disease: a randomized, placebo-controlled, double-blind, phase 2 trial. Neurology. 2015;84(21):2161–8.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    De Giorgi R, Series H. Treatment of inappropriate sexual behavior in dementia. Curr Treat Options Neurol. 2016;18(9):41.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Quill TE, Lo B, Brock DW, Meisel A. Last-resort options for palliative sedation. Ann Intern Med. 2009;151(6):421–4.PubMedCrossRefGoogle Scholar
  56. 56.
    Hendriks SA, Smalbrugge M, Hertogh CM, van der Steen JT. Dying with dementia: symptoms, treatment, and quality of life in the last week of life. J Pain Symptom Manag. 2014;47(4):710–20.CrossRefGoogle Scholar
  57. 57.
    Benitez-Rosario MA, Morita T. Palliative sedation in clinical scenarios: results of a modified Delphi study. Support Care Cancer. 2018.Google Scholar
  58. 58.
    Cherny NI, Group EGW. ESMO Clinical Practice Guidelines for the management of refractory symptoms at the end of life and the use of palliative sedation. Ann Oncol. 2014;25(Suppl 3):iii143–52.PubMedCrossRefGoogle Scholar
  59. 59.
    Gurschick L, Mayer DK, Hanson LC. Palliative sedation: an analysis of international guidelines and position statements. Am J Hosp Palliat Care. 2015;32(6):660–71.PubMedCrossRefGoogle Scholar
  60. 60.
    Bodnar J. A review of agents for palliative sedation/continuous deep sedation: pharmacology and practical applications. J Pain Palliat Care Pharmacother. 2017;31(1):16–37.PubMedCrossRefGoogle Scholar
  61. 61.
    van den Elsen GA, Ahmed AI, Verkes RJ, Kramers C, Feuth T, Rosenberg PB, et al. Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: a randomized controlled trial. Neurology. 2015;84(23):2338–46.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Savaskan E, Mueller H, Hoerr R, von Gunten A, Gauthier S. Treatment effects of Ginkgo biloba extract EGb 761(R) on the spectrum of behavioral and psychological symptoms of dementia: meta-analysis of randomized controlled trials. Int Psychogeriatr. 2018;30(3):285–93.PubMedCrossRefGoogle Scholar
  63. 63.
    Fu CY, Moyle W, Cooke M. A randomised controlled trial of the use of aromatherapy and hand massage to reduce disruptive behaviour in people with dementia. BMC Complement Altern Med. 2013;13:165.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Yoshiyama K, Arita H, Suzuki J. The effect of aroma hand massage therapy for people with dementia. J Altern Complement Med. 2015;21(12):759–65.PubMedCrossRefGoogle Scholar
  65. 65.
    O’Connor DW, Eppingstall B, Taffe J, van der Ploeg ES. A randomized, controlled cross-over trial of dermally-applied lavender (Lavandula angustifolia) oil as a treatment of agitated behaviour in dementia. BMC Complement Altern Med. 2013;13:315.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Yang MH, Lin LC, Wu SC, Chiu JH, Wang PN, Lin JG. Comparison of the efficacy of aroma-acupressure and aromatherapy for the treatment of dementia-associated agitation. BMC Complement Altern Med. 2015;15:93.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Furukawa K, Tomita N, Uematsu D, Okahara K, Shimada H, Ikeda M, et al. Randomized double-blind placebo-controlled multicenter trial of Yokukansan for neuropsychiatric symptoms in Alzheimer’s disease. Geriatr Gerontol Int. 2017;17(2):211–8.PubMedCrossRefGoogle Scholar
  68. 68.
    Teranishi M, Kurita M, Nishino S, Takeyoshi K, Numata Y, Sato T, et al. Efficacy and tolerability of risperidone, yokukansan, and fluvoxamine for the treatment of behavioral and psychological symptoms of dementia: a blinded, randomized trial. J Clin Psychopharmacol. 2013;33(5):600–7.PubMedCrossRefGoogle Scholar
  69. 69.
    • Davies SJ, Burhan AM, Kim D, Gerretsen P, Graff-Guerrero A, Woo VL, et al. Sequential drug treatment algorithm for agitation and aggression in Alzheimer’s and mixed dementia. J Psychopharmacol. 2018;32(5):509–23 Proposes treatment algorithm for BPSD, considering various manifestations of BPSD.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    • Kales HC, Lyketsos CG, Miller EM, Ballard C. Management of behavioral and psychological symptoms in people with Alzheimer’s disease: an international Delphi consensus. Int Psychogeriatr. 2018;1–8. Expert consensus regarding treatment considerations for BPSD.Google Scholar
  71. 71.
    Soto M, Andrieu S, Nourhashemi F, Ousset PJ, Ballard C, Robert P, et al. Medication development for agitation and aggression in Alzheimer disease: review and discussion of recent randomized clinical trial design. Int Psychogeriatr. 2014:1–17.Google Scholar

Copyright information

© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2019

Authors and Affiliations

  1. 1.Cambia Palliative Care Center of ExcellenceUniversity of Washington School of MedicineSeattleUSA
  2. 2.Geriatrics and Extended Care ServiceVA Puget Sound Health Care System, S-182-GECSeattleUSA
  3. 3.Division of Gerontology and Geriatric Medicine, Department of MedicineUniversity of Washington School of MedicineSeattleUSA

Personalised recommendations